PRESS RELEASE

Q3 2021 — Press release

Q3 2021PDF · 20 pages430 KB
FOR IMMEDIATE RELEASE
• 	Total sales growth of 10.7% to $23.3 Billion with operational growth of 9.9%* and adjusted operational
growth of 10.6%*
• 	Earnings per share of $1.37 increasing 3.0% and adjusted earnings per share of $2.60 increasing 18.2%*
• 	Company increasing 2021 Full-Year Guidance
New Brunswick, N.J. (October 19, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for third-
quarter 2021. “Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust
above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer
Health,” said Alex Gorsky, Chairman and Chief Executive Officer. “In the face of evolving marketplace dynamics
resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness
and agility required to meet the needs of our stakeholders, while also successfully investing in a pipeline of innovation
and key commercial platforms to drive our future growth. I am incredibly proud of our Company’s transformative growth
over the last decade. As I prepare to transition the role of CEO to Joaquin Duato in January, I want to extend my
deepest gratitude to our colleagues around the globe who work tirelessly to deliver solutions to address the world’s
most urgent and unmet healthcare challenges.”
OVERALL FINANCIAL RESULTS
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items
Q3
($ in Millions, except EPS) 	2021 	2020 	% Change
Reported Sales 	23,338	$ 	21,082	$ 	10.7%
Net Earnings 	3,667 	3,554 	3.2%
EPS (diluted) 	1.37	$ 	1.33	$ 	3.0%
Q3
Non-GAAP* ($ in Millions, except EPS) 	2021 	2020 	% Change
Operational Sales 1,2 	9.9%
Adjusted Operational Sales 1,3 	10.6%
Adjusted Net Earnings 1,4 	6,968 	5,868 	18.7%
Adjusted EPS (diluted)1,4 	2.60	$ 	2.20	$ 	18.2%

-- 1 of 20 --

REGIONAL SALES RESULTS
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
SEGMENT SALES RESULTS
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Q3
($ in Millions) 	2021 	2020 	Reported 	Operational1,2 	Currency
Adjusted
Operational1,3
U.S. 	11,963	$ 	11,086	$ 	7.9% 	7.9 	- 	8.0
International 	11,375 	9,996 	13.8% 	12.1 	1.7 	13.5
Worldwide 	23,338	$ 	21,082	$ 	10.7% 	9.9 	0.8 	10.6
% Change
Q3
($ in Millions) 	2021 	2020 	Reported 	Operational1,2 	Currency
Adjusted
Operational1,3
Consumer Health 	3,700	$ 	3,514	$ 	5.3% 	4.1 	1.2 	5.7
Pharmaceutical 	12,994 	11,418 	13.8% 	13.2 	0.6 	13.8
Medical Devices 	6,644 	6,150 	8.0% 	7.0 	1.0 	7.6
Worldwide 	23,338	$ 	21,082	$ 	10.7% 	9.9 	0.8 	10.6
% Change

-- 2 of 20 --

THIRD QUARTER 2021 SEGMENT COMMENTARY:
Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, increased
5.7%* primarily driven by over-the-counter (OTC) products. Major contributors to growth were TYLENOL and MOTRIN
analgesics, upper respiratory products, and digestive health in OTC, and AVEENO in Skin Health / Beauty.
Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 13.8%*
driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for
the treatment of a number of immune-mediated inflammatory diseases, TREMFYA (guselkumab), a biologic for the
treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,
ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate
cancer, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable
atypical antipsychotics for the treatment of schizophrenia in adults, and OPSUMIT (macitentan) an oral endothelin
receptor antagonist indicated for the treatment of pulmonary arterial hypertension to delay disease progression. Also
contributing to growth was sales of the not-for-profit COVID-19 Vaccine (Ad26.COV2.S) for the treatment of the SARS-
CoV-2 virus. This growth was partially offset by declines in U.S. sales of REMICADE (infliximab), a biologic approved
for the treatment of a number of immune-mediated inflammatory diseases, and INVOKANA (canagliflozin) for the
treatment of adults with type 2 diabetes.
Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.6%*,
driven by electrophysiology products in Interventional Solutions, wound closure products in General Surgery, surgical
vision products and contact lenses in Vision, trauma, hips, and knees in Orthopaedics, and energy, endocutters, and
biosurgicals in Advanced Surgery. Growth was partially offset by Spine, Sports & Other.

-- 3 of 20 --

NOTABLE NEW ANNOUCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures
filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on
Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases
available online in the Investors section of the company’s website at news releases.
Regulatory
Decisions
INVEGA HAFYERA (paliperidone palmitate) Receives FDA Approval For First and Only
Twice-Yearly Treatment for Adults with Schizophrenia (press release)
XARELTO (rivaroxaban) Plus Aspirin Receives FDA Approval For Expanded Peripheral
Artery Disease (PAD) Indication to Include Patients After Lower-Extremity Revascularization
(LER)
(press release)
UPTRAVI (selexipag) Receives FDA Approval For Intravenous Use in Adult Patients with
Pulmonary Arterial Hypertension (PAH) (press release)
Regulatory
Submissions
Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to
the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine 1 	(press release)
Janssen Submits Application Seeking U.S. FDA Approval of STELARA (ustekinumab) for the
Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis 1 	(press release)
Other
Alex Gorsky to Transition Role of Chief Executive Officer of Johnson & Johnson to Joaquin
Duato, Effective January 3, 2022 (press release)
Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of
Johnson & Johnson to Retire, Effective December 31, 2021 1 	(press release)
Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong
and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S. (press release)
Johnson & Johnson Issues Statement on Nationwide Opioid Settlement Agreement 	(press release)
DePuy Synthes Announces Introduction of the INHANCE Shoulder System, a First-to-Market,
Fully Integrated Shoulder Arthroplasty System (press release)
Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus
(RSV) Vaccine in Older Adults (press release)
Janssen Receives Positive CHMP Opinion for BYANNLI (six-monthly paliperidone palmitate)
for the Maintenance Treatment of Schizophrenia in Adults (press release)
Ethicon Announces ECHELON CIRCULAR Powered Stapler Associated with Major
Reduction in Serious Complications Following Colorectal Surgery (press release)
Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims 1 	(press release)
Janssen Receives Positive CHMP Opinion for RYBREVANT (amivantamab) for the
Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20
Insertion Mutations After Failure of Platinum-Based Therapy 1
(press release)
Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for
Emergency Use Authorization by U.S. FDA Advisory Committee 1 	(press release)
1Subsequent to the quarter

-- 4 of 20 --

FULL-YEAR 2021 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is
unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses,
acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These
items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in
accordance with GAAP.
($ in Billions, except EPS) 	October 2021
(Base Business)
October 2021
(incl. COVID Vx)
July 2021
(Base Business)
July 2021
(incl. COVID Vx)
Adjusted Operational
Sales 1,2
Change vs. Prior Year
9.9% - 10.5% 	12.9% - 13.5% 	9.5% - 10.5% 	12.5% - 13.5%
Operational Sales2
Change vs. Prior Year
$90.3B – 90.8B
9.4% – 10.0%
$92.8 - $93.3B
12.4% – 13.0%
$90.0B - $90.8B
9.0% – 10.0%
$92.5B - $93.3B
12.0% – 13.0%
Estimated Reported
Sales 3
Change vs. Prior Year
$91.6B - $92.1B
10.9% – 11.5%
$94.1B - $94.6B
13.9% – 14.5%
$91.3B - $92.1B
10.5% – 11.5%
$93.8B - $94.6B
13.5% – 14.5%
Adjusted Operational EPS
(Diluted)2,4
Change vs. Prior Year
$9.65 - $9.70
20.2% - 20.8%
$9.50 - $9.60
18.4% - 19.6%
Adjusted EPS (Diluted)3,4
Change vs. Prior Year
$9.77 - $9.82
21.7% - 22.3%
$9.60 - $9.70
19.6% - 20.8%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: July 2021 = $1.19 and October = $1.19 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items
Note: % may have been rounded
Other modeling considerations will be provided on the webcast.
WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m.,
Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by
visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live
webcast in the Investors section of the company's website at events-and-presentations.

-- 5 of 20 --

ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward
progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of
life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach
and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy
mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity
to profoundly change the trajectory of health for humanity.
NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding
the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted
diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible
amortization expense and special items, are non-GAAP financial measures and should not be considered
replacements for, and should be read together with, the most comparable GAAP financial measures. Except for
guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP
financial measures can be found in the accompanying financial schedules of the earnings release and the Investors
section of the company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at
quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of
earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional
information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of
selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in
the Investors section of the company's website at quarterly-results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of
1995 regarding, among other things: future operating and financial performance, product development, market
position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These
statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known
or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact
of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive
measures implemented in response, material delays and cancellations of medical procedures, supply chain
disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a
result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations;

-- 6 of 20 --

competition, including technological advances, new products and patents attained by competitors; challenges inherent
in new product research and development, including uncertainty of clinical success and obtaining regulatory
approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business
combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product
efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government
action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and
global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns
of purchasers of health care products and services; financial instability of international economies and legal systems
and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and
descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on
Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned “Cautionary Note Regarding
Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on
Form 10-Q and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these
filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking
statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to
update any forward-looking statement as a result of new information or future events or developments.
Press Contacts: 	Investor Contacts:
Courtney Dugan 	Jennifer McIntyre 	Sarah Wood 	Lisa Romanko
(347) 452-1061 	(732) 524-3922 	(732) 524-2617 	(732) 524-2034

-- 7 of 20 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2021 	2020 	Total 	Operations 	Currency 	2021 	2020 	Total 	Operations 	Currency
Sales to customers by
segment of business
Consumer Health
U.S. 	1,625	$ 	1,556 	4.5 % 	4.5 	- 	4,987	$ 	4,853 	2.8 % 	2.8 	-
International 	2,075 	1,958 	5.9 	3.7 	2.2 	5,991 	5,582 	7.3 	3.5 	3.8
3,700 	3,514 	5.3 	4.1 	1.2 	10,978 	10,435 	5.2 	3.1 	2.1
Pharmaceutical
U.S. 	7,221 	6,438 	12.2 	12.2 	- 	20,536 	18,619 	10.3 	10.3 	-
International 	5,773 	4,980 	15.9 	14.6 	1.3 	17,256 	14,685 	17.5 	12.5 	5.0
12,994 	11,418 	13.8 	13.2 	0.6 	37,792 	33,304 	13.5 	11.3 	2.2
Medical Devices
U.S. 	3,117 	3,092 	0.8 	0.8 	- 	9,470 	7,852 	20.6 	20.6 	-
International 	3,527 	3,058 	15.4 	13.3 	2.1 	10,731 	8,518 	26.0 	20.5 	5.5
6,644 	6,150 	8.0 	7.0 	1.0 	20,201 	16,370 	23.4 	20.5 	2.9
U.S. 	11,963 	11,086 	7.9 	7.9 	- 	34,993 	31,324 	11.7 	11.7 	-
International 	11,375 	9,996 	13.8 	12.1 	1.7 	33,978 	28,785 	18.0 	13.1 	4.9
Worldwide 	23,338	$ 	21,082 	10.7 % 	9.9 	0.8 	68,971	$ 	60,109 	14.7 % 	12.4 	2.3
Note: Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
THIRD QUARTER 	NINE MONTHS
Percent Change

-- 8 of 20 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2021 	2020 	Total 	Operations 	Currency 	2021 	2020 	Total 	Operations 	Currency
Sales to customers by
geographic area
U.S. 	11,963	$ 	11,086 	7.9 % 	7.9 	- 	34,993	$ 	31,324 	11.7 % 	11.7 	-
Europe 	5,587 	4,819 	15.9 	14.6 	1.3 	16,669 	13,709 	21.6 	15.3 	6.3
Western Hemisphere excluding U.S. 	1,500 	1,296 	15.7 	13.4 	2.3 	4,291 	3,931 	9.2 	8.1 	1.1
Asia-Pacific, Africa 	4,288 	3,881 	10.5 	8.5 	2.0 	13,018 	11,145 	16.8 	12.3 	4.5
International 	11,375 	9,996 	13.8 	12.1 	1.7 	33,978 	28,785 	18.0 	13.1 	4.9
Worldwide 	23,338	$ 	21,082 	10.7 % 	9.9 	0.8 	68,971	$ 	60,109 	14.7 % 	12.4 	2.3
Note: Percentages have been calculated using actual, non-rounded figures
and, therefore, may not recalculate precisely.
THIRD QUARTER 	NINE MONTHS
Percent Change

-- 9 of 20 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	23,338	$ 	100.0 	21,082	$ 	100.0 	10.7
Cost of products sold 	7,250 	31.1 	6,972 	33.1 	4.0
Gross Profit 	16,088 	68.9 	14,110 	66.9 	14.0
Selling, marketing and administrative expenses 	6,000 	25.7 	5,431 	25.8 	10.5
Research and development expense 	3,422 	14.7 	2,840 	13.5 	20.5
In-process research and development 	900 	3.9 	138 	0.6
Interest (income) expense, net 	7 	0.0 	32 	0.1
Other (income) expense, net 	1,850 	7.9 	1,200 	5.7
Restructuring 	60 	0.2 	68 	0.3
Earnings before provision for taxes on income 	3,849 	16.5 	4,401 	20.9 	(12.5)
Provision for taxes on income 	182 	0.8 	847 	4.0 	(78.5)
Net earnings 	3,667	$ 	15.7 	3,554	$ 	16.9 	3.2
Net earnings per share (Diluted) 	1.37	$ 	1.33	$ 	3.0
Average shares outstanding (Diluted) 	2,674.9 	2,669.3
Effective tax rate 	4.7 % 	19.2 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	8,058	$ 	34.5 	7,246	$ 	34.4 	11.2
Net earnings 	6,968	$ 	29.9 	5,868	$ 	27.8 	18.7
Net earnings per share (Diluted) 	2.60	$ 	2.20	$ 	18.2
Effective tax rate 	13.5 % 	19.0 %
(1) See Reconciliation of Non-GAAP Financial Measures.
THIRD QUARTER
2021 	2020

-- 10 of 20 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent 	Percent 	Increase
Amount 	to Sales 	Amount 	to Sales 	(Decrease)
Sales to customers 	68,971	$ 	100.0 	60,109	$ 	100.0 	14.7
Cost of products sold 	21,900 	31.8 	20,613 	34.3 	6.2
Gross Profit 	47,071 	68.2 	39,496 	65.7 	19.2
Selling, marketing and administrative expenses 	17,505 	25.4 	15,627 	26.0 	12.0
Research and development expense 	9,994 	14.5 	8,127 	13.5 	23.0
In-process research and development 	900 	1.3 	144 	0.3
Interest (income) expense, net 	83 	0.1 	16 	0.0
Other (income) expense, net 	480 	0.7 	545 	0.9
Restructuring 	169 	0.2 	187 	0.3
Earnings before provision for taxes on income 	17,940 	26.0 	14,850 	24.7 	20.8
Provision for taxes on income 	1,798 	2.6 	1,874 	3.1 	(4.1)
Net earnings 	16,142	$ 	23.4 	12,976	$ 	21.6 	24.4
Net earnings per share (Diluted) 	6.04	$ 	4.86	$ 	24.3
Average shares outstanding (Diluted) 	2,674.6 	2,670.8
Effective tax rate 	10.0 % 	12.6 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 	24,125	$ 	35.0 	19,827	$ 	33.0 	21.7
Net earnings 	20,517	$ 	29.7 	16,468	$ 	27.4 	24.6
Net earnings per share (Diluted) 	7.67	$ 	6.17	$ 	24.3
Effective tax rate 	15.0 % 	16.9 %
(1) See Reconciliation of Non-GAAP Financial Measures.
NINE MONTHS
2021 	2020

-- 11 of 20 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2021 	2020 	2021 	2020
Net Earnings, after tax- as reported 	$3,667 	$3,554 	$16,142 	$12,976
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,159 	1,181 	3,576 	3,426
Litigation expense, net 	2,077 	1,477 	2,054 	2,210
IPR&D 	900 	138 	900 	144
Restructuring related 	121 	130 	333 	363
Acquisition, integration and divestiture related ¹ 	20 	(154) 	(504) 	(1,087)
(Gains)/losses on securities 	(127) 	32 	(335) 	(174)
Medical Device Regulation 	59 	38 	161 	89
Other 	- 	3 	- 	6
Tax Adjustments
Tax impact on special item adjustments 2 	(849) 	(482) 	(1,097) 	(1,002)
Tax legislation and related impacts 	(59) 	(49) 	(713) 	(483)
Adjusted Net Earnings, after tax 	$6,968 	$5,868 	$20,517 	$16,468
Average shares outstanding (Diluted) 	2,674.9 	2,669.3 	2,674.6 	2,670.8
Adjusted net earnings per share (Diluted) 	$2.60 	$2.20 	$7.67 	$6.17
Operational adjusted net earnings per share (Diluted) 	$2.56 	$7.47
Notes:
1
2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the
above pre-tax special items in arriving at adjusted earnings.
Third Quarter 	Nine Months Ended
Acquisition, integration and divestiture related for the nine months of 2021 primarily includes the gain on the
divestiture of two Pharmaceutical brands outside of the U.S. Acquisition, integration and divestiture related for 2020
primarily includes a Contingent Consideration reversal ($165M in third quarter and $1,148M in nine months) related to
the timing of certain developmental milestones associated with the Auris Health acquisition.

-- 12 of 20 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	5.3% 	13.8% 	8.0% 	10.7%
U.S. 	4.5% 	12.2% 	0.8% 	7.9%
International 	5.9% 	15.9% 	15.4% 	13.8%
WW Currency 	1.2 	0.6 	1.0 	0.8
U.S. 	- 	- 	- 	-
International 	2.2 	1.3 	2.1 	1.7
WW Operational 	4.1% 	13.2% 	7.0% 	9.9%
U.S. 	4.5% 	12.2% 	0.8% 	7.9%
International 	3.7% 	14.6% 	13.3% 	12.1%
General Surgery
Advanced Sterilization Products 	0.4 	0.1
U.S. 	0.0 	0.0
International 	0.8 	0.2
Skin Health / Beauty
Dr. Ci Labo - Sedona 	1.1 	0.2
U.S. 	0.0 	0.0
International 	2.0 	0.4
All Other Acquisitions and Divestitures 	0.5 	0.6 	0.2 	0.4
U.S. 	0.6 	0.0 	0.3 	0.1
International 	0.3 	1.4 	0.0 	0.8
WW Adjusted Operational 	5.7% 	13.8% 	7.6% 	10.6%
U.S. 	5.1% 	12.2% 	1.1% 	8.0%
International 	6.1% 	16.0% 	14.1% 	13.5%
Adjusted Operational Sales Growth
THIRD QUARTER 2021 ACTUAL vs. 2020 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 13 of 20 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	5.2% 	13.5% 	23.4% 	14.7%
U.S. 	2.8% 	10.3% 	20.6% 	11.7%
International 	7.3% 	17.5% 	26.0% 	18.0%
WW Currency 	2.1 	2.2 	2.9 	2.3
U.S. 	- 	- 	- 	-
International 	3.8 	5.0 	5.5 	4.9
WW Operational 	3.1% 	11.3% 	20.5% 	12.4%
U.S. 	2.8% 	10.3% 	20.6% 	11.7%
International 	3.5% 	12.5% 	20.5% 	13.1%
General Surgery
Advanced Sterilization Products 	0.6 	0.2
U.S. 	0.0 	0.0
International 	1.2 	0.3
Skin Health / Beauty
Dr. Ci Labo - Sedona 	0.5 	0.1
U.S. 	0.0 	0.0
International 	0.9 	0.2
All Other Acquisitions and Divestitures 	0.5 	0.5 	0.2 	0.4
U.S. 	0.5 	(0.1) 	0.4 	0.1
International 	0.3 	1.3 	0.0 	0.7
WW Adjusted Operational 	4.1% 	11.8% 	21.4% 	13.1%
U.S. 	3.3% 	10.2% 	21.0% 	11.8%
International 	4.7% 	13.8% 	21.7% 	14.4%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
NINE MONTHS 2021 ACTUAL vs. 2020 ACTUAL
Segments

-- 14 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
CONSUMER HEALTH SEGMENT (2)
OTC
US 	686	$ 	601 	14.0% 	14.0% 	- 	1,960	$ 	1,917 	2.2% 	2.2% 	-
Intl 	686 	541 	26.9% 	22.8% 	4.1% 	1,894 	1,722 	10.0% 	3.9% 	6.1%
WW 	1,372 	1,142 	20.1% 	18.2% 	1.9% 	3,854 	3,639 	5.9% 	3.0% 	2.9%
SKIN HEALTH / BEAUTY
US 	569 	572 	-0.5% 	-0.5% 	- 	1,862 	1,767 	5.4% 	5.4% 	-
Intl 	555 	577 	-3.8% 	-5.5% 	1.7% 	1,595 	1,506 	5.9% 	2.1% 	3.8%
WW 	1,124 	1,149 	-2.2% 	-3.0% 	0.8% 	3,457 	3,273 	5.6% 	3.9% 	1.7%
ORAL CARE
US 	150 	164 	-8.4% 	-8.4% 	- 	478 	510 	-6.2% 	-6.2% 	-
Intl 	248 	248 	0.1% 	-1.8% 	1.9% 	762 	694 	9.9% 	5.9% 	4.0%
WW 	398 	412 	-3.3% 	-4.5% 	1.2% 	1,240 	1,204 	3.0% 	0.8% 	2.2%
BABY CARE
US 	95 	91 	5.2% 	5.2% 	- 	288 	279 	3.3% 	3.3% 	-
Intl 	296 	302 	-2.0% 	-3.1% 	1.1% 	879 	831 	5.8% 	4.6% 	1.2%
WW 	391 	393 	-0.3% 	-1.2% 	0.9% 	1,167 	1,110 	5.2% 	4.3% 	0.9%
WOMEN'S HEALTH
US 	3 	3 	20.1% 	20.1% 	- 	9 	10 	-5.7% 	-5.7% 	-
Intl 	229 	227 	0.5% 	0.6% 	-0.1% 	675 	654 	3.1% 	2.3% 	0.8%
WW 	232 	230 	0.8% 	0.8% 	0.0% 	684 	664 	3.0% 	2.1% 	0.9%
WOUND CARE / OTHER
US 	122 	125 	-2.6% 	-2.6% 	- 	390 	370 	5.3% 	5.3% 	-
Intl 	61 	64 	-5.2% 	-9.0% 	3.8% 	186 	175 	5.8% 	0.0% 	5.8%
WW 	182 	189 	-3.5% 	-4.8% 	1.3% 	575 	545 	5.4% 	3.6% 	1.8%
TOTAL CONSUMER HEALTH
US 	1,625 	1,556 	4.5% 	4.5% 	- 	4,987 	4,853 	2.8% 	2.8% 	-
Intl 	2,075 	1,958 	5.9% 	3.7% 	2.2% 	5,991 	5,582 	7.3% 	3.5% 	3.8%
WW 	3,700	$ 	3,514 	5.3% 	4.1% 	1.2% 	10,978	$ 	10,435 	5.2% 	3.1% 	2.1%
See footnotes at end of schedule
% Change 	% Change

-- 15 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
PHARMACEUTICAL SEGMENT (2,3) 	2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
IMMUNOLOGY
US 	2,771	$ 	2,558 	8.3% 	8.3% 	- 	7,932	$ 	7,330 	8.2% 	8.2% 	-
Intl 	1,480 	1,230 	20.3% 	18.8% 	1.5% 	4,464 	3,619 	23.3% 	17.6% 	5.7%
WW 	4,250 	3,789 	12.2% 	11.7% 	0.5% 	12,395 	10,950 	13.2% 	11.3% 	1.9%
REMICADE
US 	480 	634 	-24.3% 	-24.3% 	- 	1,508 	1,852 	-18.6% 	-18.6% 	-
US Exports (4) 	47 	78 	-40.2% 	-40.2% 	- 	197 	321 	-38.7% 	-38.7% 	-
Intl 	234 	209 	12.2% 	8.1% 	4.1% 	721 	673 	7.1% 	1.4% 	5.7%
WW 	761 	921 	-17.4% 	-18.3% 	0.9% 	2,426 	2,846 	-14.8% 	-16.1% 	1.3%
SIMPONI / SIMPONI ARIA
US 	295 	312 	-5.3% 	-5.3% 	- 	840 	840 	0.0% 	0.0% 	-
Intl 	276 	280 	-1.1% 	-0.7% 	-0.4% 	877 	827 	6.1% 	2.8% 	3.3%
WW 	571 	592 	-3.3% 	-3.1% 	-0.2% 	1,717 	1,667 	3.0% 	1.4% 	1.6%
STELARA
US 	1,569 	1,313 	19.5% 	19.5% 	- 	4,396 	3,668 	19.9% 	19.9% 	-
Intl 	809 	634 	27.7% 	26.3% 	1.4% 	2,404 	1,795 	33.9% 	27.5% 	6.4%
WW 	2,378 	1,947 	22.2% 	21.7% 	0.5% 	6,800 	5,463 	24.5% 	22.4% 	2.1%
TREMFYA
US 	376 	222 	69.7% 	69.7% 	- 	975 	650 	50.1% 	50.1% 	-
Intl 	161 	105 	52.5% 	50.5% 	2.0% 	459 	316 	45.4% 	38.0% 	7.4%
WW 	537 	327 	64.1% 	63.5% 	0.6% 	1,434 	965 	48.5% 	46.1% 	2.4%
OTHER IMMUNOLOGY
US 	3 	- 	* 	* 	- 	15 	- 	* 	* 	-
Intl 	0 	3 	* 	* 	* 	3 	9 	-68.6% 	-70.8% 	2.2%
WW 	3 	3 	-26.4% 	-27.5% 	1.1% 	18 	9 	91.6% 	89.5% 	2.1%
INFECTIOUS DISEASES
US 	679 	413 	64.3% 	64.3% 	- 	1,635 	1,265 	29.2% 	29.2% 	-
Intl 	709 	451 	57.2% 	55.6% 	1.6% 	1,788 	1,397 	28.0% 	23.2% 	4.8%
WW 	1,389 	864 	60.6% 	59.8% 	0.8% 	3,424 	2,662 	28.6% 	26.1% 	2.5%
COVID-19 VACCINE
US 	270 	- 	* 	* 	- 	421 	- 	* 	* 	-
Intl 	233 	- 	* 	* 	- 	346 	- 	* 	* 	-
WW 	502 	- 	* 	* 	- 	766 	- 	* 	* 	-
EDURANT / rilpivirine
US 	12 	11 	8.4% 	8.4% 	- 	31 	33 	-4.8% 	-4.8% 	-
Intl 	247 	226 	9.7% 	8.7% 	1.0% 	733 	684 	7.2% 	1.7% 	5.5%
WW 	259 	236 	9.6% 	8.6% 	1.0% 	764 	716 	6.7% 	1.4% 	5.3%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	380 	379 	0.4% 	0.4% 	- 	1,128 	1,154 	-2.2% 	-2.2% 	-
Intl 	137 	147 	-7.1% 	-8.8% 	1.7% 	440 	461 	-4.6% 	-8.6% 	4.0%
WW 	517 	526 	-1.7% 	-2.2% 	0.5% 	1,568 	1,615 	-2.9% 	-4.1% 	1.2%
OTHER INFECTIOUS DISEASES
US 	18 	24 	-26.0% 	-26.0% 	- 	55 	79 	-29.6% 	-29.6% 	-
Intl 	93 	78 	18.3% 	15.2% 	3.1% 	270 	252 	6.9% 	2.6% 	4.3%
WW 	110 	102 	7.8% 	5.4% 	2.4% 	325 	331 	-1.8% 	-5.0% 	3.2%
% Change 	% Change

-- 16 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
NEUROSCIENCE
US 	835 	759 	10.2% 	10.2% 	- 	2,448 	2,285 	7.2% 	7.2% 	-
Intl 	854 	846 	0.8% 	-0.5% 	1.3% 	2,770 	2,565 	8.0% 	4.1% 	3.9%
WW 	1,689 	1,605 	5.3% 	4.6% 	0.7% 	5,218 	4,850 	7.6% 	5.5% 	2.1%
CONCERTA / Methylphenidate
US 	35 	43 	-19.5% 	-19.5% 	- 	117 	150 	-22.1% 	-22.1% 	-
Intl 	122 	107 	14.2% 	12.5% 	1.7% 	372 	319 	16.4% 	11.6% 	4.8%
WW 	157 	149 	4.5% 	3.3% 	1.2% 	489 	469 	4.1% 	0.8% 	3.3%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	648 	585 	11.0% 	11.0% 	- 	1,882 	1,704 	10.4% 	10.4% 	-
Intl 	355 	341 	4.3% 	3.2% 	1.1% 	1,111 	983 	13.0% 	7.6% 	5.4%
WW 	1,004 	926 	8.5% 	8.1% 	0.4% 	2,994 	2,688 	11.4% 	9.4% 	2.0%
RISPERDAL CONSTA
US 	71 	70 	1.3% 	1.3% 	- 	210 	220 	-4.7% 	-4.7% 	-
Intl 	69 	81 	-16.7% 	-16.0% 	-0.7% 	242 	254 	-5.1% 	-8.3% 	3.2%
WW 	140 	152 	-8.4% 	-8.0% 	-0.4% 	452 	475 	-4.9% 	-6.6% 	1.7%
OTHER NEUROSCIENCE
US 	81 	60 	34.7% 	34.7% 	- 	239 	210 	13.9% 	13.9% 	-
Intl 	307 	317 	-2.9% 	-4.8% 	1.9% 	1,045 	1,008 	3.7% 	1.5% 	2.2%
WW 	388 	377 	3.1% 	1.5% 	1.6% 	1,284 	1,218 	5.5% 	3.6% 	1.9%
ONCOLOGY
US 	1,525 	1,267 	20.3% 	20.3% 	- 	4,364 	3,623 	20.4% 	20.4% 	-
Intl 	2,140 	1,862 	14.9% 	13.8% 	1.1% 	6,406 	5,310 	20.6% 	15.3% 	5.3%
WW 	3,665 	3,129 	17.1% 	16.5% 	0.6% 	10,770 	8,933 	20.6% 	17.4% 	3.2%
DARZALEX
US 	841 	585 	43.7% 	43.7% 	- 	2,302 	1,540 	49.5% 	49.5% 	-
Intl 	739 	514 	43.7% 	42.0% 	1.7% 	2,076 	1,397 	48.6% 	42.2% 	6.4%
WW 	1,580 	1,099 	43.7% 	42.9% 	0.8% 	4,378 	2,937 	49.1% 	46.0% 	3.1%
ERLEADA
US 	214 	152 	40.5% 	40.5% 	- 	578 	407 	41.8% 	41.8% 	-
Intl 	130 	55 	* 	* 	* 	329 	112 	* 	* 	*
WW 	344 	206 	66.7% 	65.8% 	0.9% 	907 	519 	74.7% 	72.2% 	2.5%
IMBRUVICA
US 	413 	450 	-8.3% 	-8.3% 	- 	1,311 	1,329 	-1.3% 	-1.3% 	-
Intl 	654 	581 	12.6% 	10.9% 	1.7% 	1,996 	1,682 	18.7% 	13.1% 	5.6%
WW 	1,066 	1,031 	3.5% 	2.5% 	1.0% 	3,307 	3,011 	9.9% 	6.7% 	3.2%
ZYTIGA / abiraterone acetate
US 	25 	58 	-57.0% 	-57.0% 	- 	96 	284 	-66.2% 	-66.2% 	-
Intl 	523 	532 	-1.8% 	-2.1% 	0.3% 	1,653 	1,564 	5.7% 	0.9% 	4.8%
WW 	548 	590 	-7.2% 	-7.5% 	0.3% 	1,749 	1,848 	-5.4% 	-9.4% 	4.0%
OTHER ONCOLOGY
US 	32 	21 	49.6% 	49.6% 	- 	76 	63 	21.0% 	21.0% 	-
Intl 	94 	181 	-48.0% 	-47.2% 	-0.8% 	352 	556 	-36.6% 	-38.5% 	1.9%
WW 	126 	203 	-37.6% 	-36.9% 	-0.7% 	428 	619 	-30.7% 	-32.4% 	1.7%
% Change 	% Change

-- 17 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
PULMONARY HYPERTENSION
US 	610 	510 	19.7% 	19.7% 	- 	1,778 	1,541 	15.4% 	15.4% 	-
Intl 	258 	239 	7.9% 	8.4% 	-0.5% 	821 	742 	10.7% 	7.3% 	3.4%
WW 	868 	749 	15.9% 	16.1% 	-0.2% 	2,599 	2,283 	13.9% 	12.7% 	1.2%
OPSUMIT
US 	299 	244 	22.8% 	22.8% 	- 	861 	729 	18.2% 	18.2% 	-
Intl 	159 	148 	7.4% 	7.8% 	-0.4% 	510 	458 	11.3% 	7.7% 	3.6%
WW 	458 	392 	17.0% 	17.1% 	-0.1% 	1,371 	1,187 	15.5% 	14.1% 	1.4%
UPTRAVI
US 	265 	226 	17.3% 	17.3% 	- 	792 	692 	14.6% 	14.6% 	-
Intl 	44 	34 	30.4% 	28.8% 	1.6% 	135 	100 	34.6% 	27.9% 	6.7%
WW 	309 	260 	19.0% 	18.8% 	0.2% 	927 	792 	17.1% 	16.2% 	0.9%
OTHER PULMONARY HYPERTENSION
US 	47 	40 	14.4% 	14.4% 	- 	125 	121 	2.8% 	2.8% 	-
Intl 	54 	57 	-4.4% 	-2.1% 	-2.3% 	176 	183 	-3.7% 	-5.0% 	1.3%
WW 	101 	97 	3.4% 	4.8% 	-1.4% 	301 	304 	-1.1% 	-1.9% 	0.8%
CARDIOVASCULAR / METABOLISM / OTHER
US 	800 	931 	-14.0% 	-14.0% 	- 	2,379 	2,574 	-7.6% 	-7.6% 	-
Intl 	333 	351 	-5.1% 	-8.2% 	3.1% 	1,007 	1,052 	-4.2% 	-9.3% 	5.1%
WW 	1,133 	1,281 	-11.5% 	-12.4% 	0.9% 	3,386 	3,625 	-6.6% 	-8.1% 	1.5%
XARELTO
US 	636 	630 	0.8% 	0.8% 	- 	1,794 	1,716 	4.5% 	4.5% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	636 	630 	0.8% 	0.8% 	- 	1,794 	1,716 	4.5% 	4.5% 	-
INVOKANA / INVOKAMET
US 	66 	156 	-57.4% 	-57.4% 	- 	249 	405 	-38.4% 	-38.4% 	-
Intl 	67 	68 	-1.0% 	-4.3% 	3.3% 	194 	173 	11.9% 	5.8% 	6.1%
WW 	133 	224 	-40.3% 	-41.3% 	1.0% 	443 	578 	-23.4% 	-25.2% 	1.8%
PROCRIT / EPREX
US 	47 	69 	-30.9% 	-30.9% 	- 	168 	215 	-21.7% 	-21.7% 	-
Intl 	65 	63 	3.1% 	0.5% 	2.6% 	198 	208 	-4.7% 	-9.7% 	5.0%
WW 	112 	132 	-14.6% 	-15.8% 	1.2% 	366 	423 	-13.4% 	-15.8% 	2.4%
OTHER
US 	51 	75 	-32.6% 	-32.6% 	- 	168 	238 	-29.3% 	-29.3% 	-
Intl 	200 	219 	-8.7% 	-11.9% 	3.2% 	615 	670 	-8.3% 	-13.1% 	4.8%
WW 	251 	294 	-14.8% 	-17.2% 	2.4% 	783 	908 	-13.8% 	-17.3% 	3.5%
TOTAL PHARMACEUTICAL
US 	7,221 	6,438 	12.2% 	12.2% 	- 	20,536 	18,619 	10.3% 	10.3% 	-
Intl 	5,773 	4,980 	15.9% 	14.6% 	1.3% 	17,256 	14,685 	17.5% 	12.5% 	5.0%
WW 	12,994	$ 	11,418 	13.8% 	13.2% 	0.6% 	37,792	$ 	33,304 	13.5% 	11.3% 	2.2%
% Change 	% Change

-- 18 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
MEDICAL DEVICES SEGMENT (2) 	2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
INTERVENTIONAL SOLUTIONS
US 	444	$ 	399 	11.1% 	11.1% 	- 	1,353 	1,019 	32.7% 	32.7% 	-
Intl 	513 	437 	17.7% 	15.1% 	2.6% 	1,599 	1,134 	41.1% 	34.3% 	6.8%
WW 	957 	836 	14.5% 	13.2% 	1.3% 	2,952 	2,153 	37.1% 	33.6% 	3.5%
ORTHOPAEDICS
US 	1,249 	1,308 	-4.5% 	-4.5% 	- 	3,821 	3,427 	11.5% 	11.5% 	-
Intl 	843 	774 	8.8% 	6.8% 	2.0% 	2,611 	2,145 	21.7% 	15.4% 	6.3%
WW 	2,093 	2,083 	0.5% 	-0.3% 	0.8% 	6,433 	5,572 	15.4% 	13.0% 	2.4%
HIPS
US 	210 	221 	-5.3% 	-5.3% 	- 	654 	564 	15.9% 	15.9% 	-
Intl 	146 	124 	18.8% 	16.0% 	2.8% 	451 	344 	31.3% 	24.1% 	7.2%
WW 	356 	345 	3.3% 	2.3% 	1.0% 	1,105 	908 	21.8% 	19.0% 	2.8%
KNEES
US 	184 	205 	-9.8% 	-9.8% 	- 	579 	527 	10.0% 	10.0% 	-
Intl 	131 	102 	28.1% 	25.9% 	2.2% 	403 	298 	35.4% 	28.2% 	7.2%
WW 	316 	308 	2.8% 	2.1% 	0.7% 	983 	825 	19.2% 	16.6% 	2.6%
TRAUMA
US 	455 	433 	5.3% 	5.3% 	- 	1,352 	1,194 	13.3% 	13.3% 	-
Intl 	260 	253 	2.4% 	0.9% 	1.5% 	805 	698 	15.2% 	9.5% 	5.7%
WW 	715 	685 	4.2% 	3.7% 	0.5% 	2,157 	1,892 	14.0% 	11.9% 	2.1%
SPINE, SPORTS & OTHER
US 	400 	449 	-11.1% 	-11.1% 	- 	1,236 	1,142 	8.2% 	8.2% 	-
Intl 	306 	295 	3.5% 	1.5% 	2.0% 	952 	805 	18.2% 	12.0% 	6.2%
WW 	705 	745 	-5.3% 	-6.1% 	0.8% 	2,187 	1,947 	12.3% 	9.7% 	2.6%
% Change 	% Change

-- 19 of 20 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
THIRD QUARTER 	NINE MONTHS
2021 	2020 	Reported 	Operational (1) 	Currency 	2021 	2020 	Reported 	Operational (1) 	Currency
SURGERY
US 	948 	913 	3.9% 	3.9% 	- 	2,881 	2,247 	28.2% 	28.2% 	-
Intl 	1,457 	1,239 	17.6% 	14.8% 	2.8% 	4,418 	3,556 	24.2% 	18.4% 	5.8%
WW 	2,405 	2,152 	11.8% 	10.2% 	1.6% 	7,299 	5,803 	25.8% 	22.2% 	3.6%
ADVANCED
US 	440 	421 	4.6% 	4.6% 	- 	1,304 	1,079 	20.9% 	20.9% 	-
Intl 	705 	579 	21.8% 	18.4% 	3.4% 	2,126 	1,644 	29.3% 	23.1% 	6.2%
WW 	1,144 	1,000 	14.6% 	12.6% 	2.0% 	3,430 	2,723 	26.0% 	22.2% 	3.8%
GENERAL
US 	508 	492 	3.3% 	3.3% 	- 	1,577 	1,168 	35.0% 	35.0% 	-
Intl 	752 	660 	13.9% 	11.7% 	2.2% 	2,292 	1,912 	19.9% 	14.5% 	5.4%
WW 	1,261 	1,152 	9.4% 	8.1% 	1.3% 	3,869 	3,080 	25.6% 	22.3% 	3.3%
VISION
US 	475 	473 	0.6% 	0.6% 	- 	1,414 	1,160 	21.9% 	21.9% 	-
Intl 	714 	608 	17.4% 	17.4% 	0.0% 	2,103 	1,683 	25.0% 	22.0% 	3.0%
WW 	1,189 	1,081 	10.1% 	10.0% 	0.1% 	3,517 	2,843 	23.7% 	22.0% 	1.7%
CONTACT LENSES / OTHER
US 	359 	375 	-4.3% 	-4.3% 	- 	1,082 	924 	17.0% 	17.0% 	-
Intl 	522 	455 	14.9% 	15.2% 	-0.3% 	1,525 	1,274 	19.8% 	17.3% 	2.5%
WW 	882 	830 	6.2% 	6.4% 	-0.2% 	2,607 	2,198 	18.6% 	17.2% 	1.4%
SURGICAL
US 	117 	98 	19.6% 	19.6% 	- 	333 	236 	41.1% 	41.1% 	-
Intl 	191 	153 	24.7% 	23.7% 	1.0% 	577 	409 	41.1% 	36.7% 	4.4%
WW 	308 	251 	22.7% 	22.1% 	0.6% 	910 	645 	41.1% 	38.3% 	2.8%
TOTAL MEDICAL DEVICES
US 	3,117 	3,092 	0.8% 	0.8% 	- 	9,470 	7,852 	20.6% 	20.6% 	-
Intl 	3,527 	3,058 	15.4% 	13.3% 	2.1% 	10,731 	8,518 	26.0% 	20.5% 	5.5%
WW 	6,644	$ 	6,150 	8.0% 	7.0% 	1.0% 	20,201	$ 	16,370 	23.4% 	20.5% 	2.9%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Certain prior year amounts have been reclassified to conform to current year product disclosures
(4) Reported as U.S. sales
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
% Change 	% Change

-- 20 of 20 --